1 Reframing “Benign” Disease: The Modern Clinical Impact of Indolent Systemic Mastocytosis

Indolent systemic mastocytosis (ISM) has historically been labeled a “benign” hematologic disorder on the basis of life expectancy, yet contemporary clinical experience underscores its substantial impact on morbidity and quality of life. Traditional classifications divided mastocytosis into benign and malignant variants according to survival, placing ISM in the former category and advanced systemic mastocytosis, including aggressive forms and those associated with other myeloid neoplasms, in the latter. Clinicians now recognize that many patients with ISM experience disabling multisystem symptoms that are disproportionate to the ostensibly indolent natural history of the disease and that the “benign” designation can be misleading from a patient-centered standpoint.

Disease expression in ISM is heterogeneous, ranging from asymptomatic individuals requiring only intermittent medications to patients with severe, refractory symptomatology despite optimized anti–mast cell mediator regimens. Conventional symptomatic approaches—primarily H1 and H2 antihistamines, leukotriene antagonists, and mast cell stabilizers—may attenuate mediator-related symptoms such as flushing and pruritus but do not alter the underlying mast cell burden. Visible cutaneous lesions often persist, contributing to psychosocial distress, and patients may be exposed to polypharmacy, with attendant adverse effects including sedation, weight gain, and fatigue. In addition, systemic complications such as recurrent anaphylaxis and osteoporosis with pathologic fractures remain important sources of morbidity and represent clear areas of unmet need.

Within this context, newer therapies targeting the KIT D816V driver mutation have begun to change the therapeutic landscape for ISM, particularly for patients whose symptoms remain uncontrolled with best available supportive care. These agents directly address the clonal mast cell compartment by reducing the burden of mutated cells, thereby offering the possibility of more profound and durable symptom relief. In this video discussion, Cem Akin, MD, reviews how the evolving understanding of ISM biology, coupled with the advent of selective KIT inhibition, has reframed both disease perception and treatment goals for patients with indolent systemic mastocytosis. Akin emphasizes the need to move beyond a purely “benign vs malignant” framework toward a model that incorporates quality of life, comorbidity burden, and long-term disease management.